Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial

EP: 1.Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

EP: 2.Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

EP: 3.Application of Real-World Evidence in Selecting CAR T in R/R MM

EP: 4.Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

EP: 5.Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

EP: 6.Future of Bispecifics and CAR T in R/R MM

EP: 7.Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL

Now Viewing

EP: 8.Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial

EP: 9.Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

EP: 10.Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

EP: 11.Implications of BTK Inhibitors Combined With CAR-T in R/R CLL/SLL

EP: 12.Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL

EP: 13.Insights From Augmented Hyper-CVAD (AHCVAD), a Pediatric-Inspired Regimen for Adults Younger Than 50 Years With ALL

EP: 14.Key Takeaways From ASH 2024

EP: 15.Looking Into the Future of AML Treatments

EP: 16.Looking Ahead For the Treatments of R/R MM

EP: 17.Recommendations For Future Clinical Trials in R/R MM

EP: 18.Treatment and Management of MM with Amyloidosis

EP: 19.Highlighting the Key Takeaways From ASH 2024

Video content above is prompted by the following:

Iopofosine I 131 in Previously Treated WM

Study Overview:
The phase 2 CLOVER-WaM trial evaluated the efficacy and safety of iopofosine I 131, a targeted radiopharmaceutical, in patients with previously treated WM. This international, multicenter, open-label study (ASH 2024, abstract #861) demonstrated promising clinical activity in a population with limited treatment options.

Key Findings:

• Efficacy: Iopofosine I 131 showed meaningful response rates, suggesting a potential role in relapsed or refractory WM.
• Safety Profile: The treatment was generally well tolerated, with manageable adverse events, supporting its feasibility for integration into clinical practice.

Potential Impact on WM Treatment Paradigm:
The introduction of iopofosine I 131 could expand therapeutic options for WM, particularly for patients with resistance or intolerance to standard therapies. As a novel radiopharmaceutical, it introduces a targeted radiation-based approach, complementing existing chemotherapy, Bruton tyrosine kinase inhibitors, and monoclonal antibodies.

Future Research Implications:

• Combination Strategies: Exploring synergies between iopofosine I 131 and current WM therapies
• Earlier-Line Integration: Investigating its role in earlier treatment settings to improve long-term outcomes
• Biomarker Identification: Defining patient subgroups most likely to benefit from radiopharmaceutical therapy
• Comparative Studies: Evaluating its effectiveness vs existing standard-of-care options

The results from CLOVER-WaM highlight iopofosine I 131 as a promising addition to the WM treatment landscape, warranting further investigation in future clinical trials.